Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial
- Line Brøndum*
- , Jan Alsner
- , Brita Singers Sørensen
- , Christian Maare
- , Jørgen Johansen
- , Hanne Primdahl
- , Jan Folkvard Evensen
- , Claus Andrup Kristensen
- , Lisbeth Juhler Andersen
- , Jens Overgaard
- , Jesper Grau Eriksen
*Kontaktforfatter
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review